Skip to content
Sexuality – Lifestyle
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
May 28, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
April 15, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
April 9, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
March 23, 2026